Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
NCT02752906
Completed
The aim of the study was to describe the safety and antibody response to booster administration with Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine in participants who received their first quadrivalent meningococcal Conjugate vaccine dose in the past 4-10 years. Primary Objective: * To demonstrate the non-inferiority of the vaccine seroresponse of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of MenACY... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
03/24/2022
Locations: Investigational Site Number 016, Birmingham, Alabama +29 locations
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Register for Updates
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years
NCT03077438
Completed
The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) vaccine in children 2 to 9 years of age in the United States (US) and Puerto Rico. Primary objective: - To demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y... Read More
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
03/21/2022
Locations: Investigational Site, Birmingham, Alabama +35 locations
Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Register for Updates
A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers
NCT01049035
Completed
The purpose of this study was to evaluate the optimal vaccination schedule for a Quadrivalent Meningococcal Polysaccharide (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (MenACYW Conjugate vaccine) in order to provide an effective protein conjugate quadrivalent meningococcal vaccine in the population with the highest incidence of disease. Objectives: * To describe the safety profile of MenACYW Conjugate vaccine administered at 5 different schedules and concomitantly with routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 365 days
Trial Updated:
03/21/2022
Locations: Not set, Birmingham, Alabama +24 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
NCT02915302
Completed
The aim of the study was to describe the safety and immunogenicity of a 0.5-mL dose (15 μg hemagglutinin \[HA\] per strain) of Fluzone Quadrivalent vaccine in children 6 to \<36 months of age. Primary objective: * To compare the rate of any fever (temperature ≥100.4 degrees Fahrenheit \[38.0 degrees Celsius) following a 0.5-mL dose of Fluzone Quadrivalent vaccine to that following a 0.25-mL dose of Fluzone Quadrivalent vaccine during the 7 days after either vaccination (Dose 1 and Dose 2 combi... Read More
Gender:
ALL
Ages:
Between 6 months and 35 months
Trial Updated:
03/15/2022
Locations: Not set, Birmingham, Alabama +35 locations
Conditions: Influenza
Register for Updates
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
NCT03617523
Completed
The primary objectives of this study were: * To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent vaccine in children 6 to less than (\<) 36 months of age and 3 to \<9 years of age, and in adults 18 to \<65 years of age; the immunogenicity of the 2018-2019 formulation of Flublok® Quadrivalent vaccine in adults 18 to \<65 years of age; and the immunogenicity of the 2018-2019 formulation of Fluzone High-Dose vaccine in adults greater than or equal to (\>=) 65 years... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
03/15/2022
Locations: Investigational Site Number 8400003, Bardstown, Kentucky +2 locations
Conditions: Influenza
Register for Updates
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
NCT01943825
Completed
The aim of the study was to evaluate a compressed dosing schedule and the immunologic effects of co-administration of a CYD dengue vaccine with a licensed flavivirus (FV) with Japanese encephalitis (JE) vaccine. Primary Objectives: * To describe and compare the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after each CYD dengue vaccine dose. * To describe the persistence of the humoral immune response to each of the 4 parental dengue virus ser... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/15/2022
Locations: Not set, Syracuse, New York
Conditions: Dengue, Dengue Fever, Dengue Hemorrhagic Fever
Register for Updates
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
NCT02908269
Completed
The aim of the study was to describe the safety and immunogenicity of the 2016-2017 formulations of Fluzone Quadrivalent vaccine in children 3 to \< 9 years of age and in adults 18 to \< 65 years or age, and of the 2016-2017 formulation of Fluzone High-Dose vaccine in adults ≥65 years of age. Primary Observational Objectives * To describe the safety of the 2016-2017 formulation of Fluzone Quadrivalent vaccine in children 3 to \< 9 years of age and adults 18 to \< 65 years of age, and the safet... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
03/15/2022
Locations: Not set, Bardstown, Kentucky +1 locations
Conditions: Influenza
Register for Updates
Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine
NCT01488890
Completed
The aim of this study was to evaluate the administration of CYD dengue vaccine serotypes (1, 2, 3 and 4) following a compressed schedule in 3 different populations. Primary Objectives: * To describe the humoral immune response to each of the 4 parental dengue virus serotypes at baseline and 28 days after CYD dengue vaccine Dose 3 in Group 1 (Month \[M\] 13) and Group 2 (M07), irrespective of whether or not Yellow Fever (YF) vaccine has been previously administered. * To describe the persistenc... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/15/2022
Locations: Not set, Alabaster, Alabama +6 locations
Conditions: Dengue, Dengue Fever, Dengue Hemorrhagic Fever, Yellow Fever
Register for Updates
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
NCT02587520
Completed
This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US). Primary Objective * To describe the safety profile of each SP0173 investigational formulation. Observational Objective: * To describe the immunogenicity of each SP0173 investigational formulation.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
03/15/2022
Locations: Not set, Birmingham, Alabama +19 locations
Conditions: Tetanus, Diphtheria, Pertussis, Whooping Cough
Register for Updates
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
NCT03308825
Completed
The aim of the study was to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone Quadrivalent vaccine in children 6 months to \< 9 years of age, and in adults 18 to \< 65 years of age, and to describe the safety and immunogenicity of the 2017-2018 formulation of Fluzone High-Dose vaccine in adults ≥ 65 years of age.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
03/15/2022
Locations: Sanofi Pasteur Investigational Site 003, Council Bluffs, Iowa +2 locations
Conditions: Influenza, Flu
Register for Updates
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
NCT01061840
Completed
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting antigen presentation. The furin bifunctional shRNA blocks furin protein production at the post transcriptional and translational levels. This decrease in furin in turn decreases the conversion of the proforms TGFβ1 and TGFβ2 proteins. Also, reduced furin protein levels h... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/14/2022
Locations: Florida Cancer Specialists, West Palm Beach, Florida +3 locations
Conditions: Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
Register for Updates
Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
NCT02362451
Terminated
Background: - Men who continue to have an elevated or rising prostate specific antigen (PSA) level after their primary prostate cancer treatment are at increased risk for their cancer to progress. The time it takes to progress is highly variable. One way to predict this progression is based on the change in PSA levels over time. This is called the PSA doubling time (PSADT). Researchers want to test a vaccine on men with Stage D0 prostate cancer. Stage D0 means the PSA has become detectable agai... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/10/2022
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostate Cancer
Register for Updates